0000000000022723

AUTHOR

Sören Schwuchow-thonke

showing 4 related works from this author

Management of Oral Anti-Coagulation in Patients with Heart Failure-Insights from the ThrombEVAL Study

2018

AbstractPatients with heart failure (HF) are frequently anti-coagulated with vitamin K-antagonists (VKAs). The use of long-acting VKA may be preferable for HF patients due to higher stability of plasma concentrations. However, evidence on phenprocoumon-based oral anti-coagulation (OAC) therapy in HF is scarce. The aim of this study was to assess the impact of the presence of HF on quality of phenprocoumon-based OAC and the subsequent clinical outcome. Quality of OAC therapy and the incidence of adverse events were analysed in a cohort of regular care (n = 2,011) from the multi-centre thrombEVAL study program (NCT01809015) stratified by the presence of HF. To assess the modifiability of outc…

MaleAdministration Oralheart failureclinical outcomeED AMERICAN-COLLEGE030204 cardiovascular system & hematologyTHERAPY ANTITHROMBOTIC THERAPYCohort StudiesPhenprocoumon0302 clinical medicinequality of careGermanyProspective Studies030212 general & internal medicineProspective cohort studyAged 80 and overOUTCOMESIncidenceHazard ratioHematologyTreatment OutcomeCohortFemaleCLINICAL-PRACTICE GUIDELINESSINUS RHYTHMmedicine.drugCohort studyRiskmedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsHemorrhageWARFARINEJECTION FRACTION03 medical and health sciencesInternal medicinemedicineHumansAdverse effectAgedbusiness.industryWarfarinhealth care modelAnticoagulantsmedicine.diseaseoral anti-coagulationHeart failureATRIAL-FIBRILLATIONPhenprocoumonADVERSE EVENTSbusinessANTICOAGULANT-THERAPY
researchProduct

FEV1 Predicts Cardiac Status and Outcome in Chronic Heart Failure

2022

Background COPD is an established predictor of clinical outcome in patients with chronic heart failure (HF). However, little evidence is available about the predictive value of FEV1 in chronic HF. Research Question Is pulmonary function related to the progression of chronic HF? Study Design and Methods The MyoVasc study ( ClinicalTrials.gov Identifier: NCT04064450) is a prospective cohort study of HF. Information on pulmonary and cardiac functional and structural status was obtained by body plethysmography and echocardiography. The primary study end point was worsening of HF. Results Overall 2,998 participants (age range, 35-84 years) with available FEV1 data were eligible for analysis. Lin…

Pulmonary and Respiratory MedicineCardiac function curvemedicine.medical_specialtyCOPDEjection fractionbusiness.industryDiastoleCritical Care and Intensive Care Medicinemedicine.diseasePulmonary function testingInternal medicineHeart failureCardiologyMedicineCardiology and Cardiovascular MedicinebusinessHeart failure with preserved ejection fractionProspective cohort studyChest
researchProduct

Sex-Specific Relationship Between Parathyroid Hormone and Platelet Indices in Phenotypes of Heart Failure—Results From the MyoVasc Study

2021

Background: Heart failure (HF) is a multifactorial syndrome with pathophysiological complexities still not fully understood. Higher mean platelet volume (MPV), a potential marker of platelet activation, and high concentrations of parathyroid hormone (PTH) have been implicated in the pathogenesis of HF.Aim: This study aims to investigate sex-specifically the association between PTH concentrations and platelet indices in phenotypes of HF.Methods and Results: PTH and platelet indices (MPV and platelet count) were available in 1,896 participants from the MyoVasc study in Mainz, Germany. Multivariable linear regression models, adjusted for age, sex, season, vitamin D status, cardiovascular risk …

heart failure with preserved ejection fractionBIOMARKERmedicine.medical_specialtyPATHOPHYSIOLOGYheart failureParathyroid hormoneCardiovascular Medicine030204 cardiovascular system & hematologyMPVDISEASE03 medical and health sciences0302 clinical medicineInternal medicineMANAGEMENTVitamin D and neurologymedicineDiseases of the circulatory (Cardiovascular) systemparathyroid hormoneheart failure with reduced ejection fractionPlatelet030212 general & internal medicinePlatelet activationMean platelet volumeVITAMIN-DOriginal ResearchRISKEjection fractionbusiness.industryMORTALITYplatelet countmedicine.diseaseDYSFUNCTIONEndocrinologyRC666-701Heart failureCardiology and Cardiovascular MedicineHeart failure with preserved ejection fractionbusinessFrontiers in Cardiovascular Medicine
researchProduct

Association of Global Longitudinal Strain With Clinical Status and Mortality in Patients With Chronic Heart Failure.

2021

IMPORTANCE: Global longitudinal strain (GLS) is an emerging echocardiographic biomarker of cardiac function in heart failure (HF). Evidence from large-scale studies comprehensively investigating GLS for its association with clinical phenotypes and mortality in asymptomatic and symptomatic chronic HF is limited. OBJECTIVE: To assess the factors associated with GLS and its prognostic value in patients with chronic HF. DESIGN, SETTING, AND PARTICIPANTS: The observational, prospective MyoVasc cohort study enrolled 3289 individuals with asymptomatic to symptomatic HF between January 17, 2013, and April 27, 2018. The median follow-up was 3.2 years (interquartile range, 2.0-4.0 years). Participant…

Cardiac function curveMalemedicine.medical_specialty030204 cardiovascular system & hematologyAsymptomatic03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicinemedicineHumans030212 general & internal medicineMyocardial infarctionProspective StudiesAgedOriginal InvestigationHeart Failurebusiness.industryHazard ratioPatient AcuityAtrial fibrillationHeartMiddle Agedmedicine.diseasePrognosisEchocardiographyHeart failureFemalemedicine.symptomCardiology and Cardiovascular MedicinebusinessBiomarkersCohort studyJAMA cardiology
researchProduct